FRUZAQLA® (fruquintinib)
for Metastatic Colorectal Cancer via NPP
Patient Background
A 62-year-old retired banker from Thrissur, Kerala, was diagnosed with metastatic colorectal cancer. After failure of multiple chemotherapy lines and biologics, treatment options were limited. Senior Oncologist at Kochi, suggested FRUZAQLA® (fruquintinib)—a selective VEGFR inhibitor approved internationally for refractory mCRC.
Access Challenges
- Not commercially available in India
- Limited awareness about NPP among patients
- Concerns regarding authenticity and legality
MitoGENE was introduced as a specialized NPP access partner.
Regulatory Execution
MitoGENE ensured:
Outcome
FRUZAQLA® was successfully imported and administered as per the treatment plan. The patient tolerated therapy well and continued treatment under close medical supervision.
MitoGENE’s Role
Provide Ethical Access
Regulatory adherence
Transparent pricing
Patient-centric coordination
Disclaimer:
The product mentioned is not approved for commercial sale in India. Access was provided strictly for personal use under physician supervision in accordance with CDSCO’s Named Patient Program (Form 12B). MitoGENE does not promote or sell unapproved drugs.